Today we are two distinct companies: Baxter $BAX and Baxalta $BXLT, now trading on @NYSE.
Baxter Announces Plans to Create Two Separate Leading Global Healthcare Companies. bit.ly/1rEN28w
FDA Approves Baxter's Recombinant Factor IX to Treat Children with Hemophilia B. bit.ly/1s9QoNW
Sharing perspectives on successful collaboration between large and small companies bit.ly/1VZXqcf @asissel and Adam Berman, TVA Med
Baxter files for US FDA approval of extended half-life rFVIII for #hemophilia A. bit.ly/12fhFtr
Baxter Announces Baxalta as the Name of the New Global Biopharmaceutical Company. bit.ly/1rJ4B4u